December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

35.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗
Via Stocktwits
News headline image
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain ↗
Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross. 
Via Benzinga
News headline image
Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils ↗
Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria. 
Via Benzinga
News headline image
Here's Why Shares in Viking Therapeutics Shot Higher in October ↗
Three factors took Viking's shares higher in the month. 
Via The Motley Fool
News headline image
Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets. ↗
It's a great idea to watch the latest moves of this expert investor. 
Via The Motley Fool
Topics Artificial Intelligence
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera ↗
Via Stocktwits
News headline image
Earnings Preview For Viking Therapeutics ↗
 
Via Benzinga
News headline image
Prediction: The Next Eli Lilly Might Already Be Trading Under $50 ↗
Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left. 
Via The Motley Fool
News headline image
Should You Buy Viking Therapeutics Before Nov. 5? ↗
Viking's stock surged in one trading session after a positive clinical trial report last year. 
Via The Motley Fool
News headline image
3 Promising Growth Stocks That Are Down Around 60% From Their Highs ↗
These stocks may be down as of late, but investors shouldn't count them out in the long run. 
Via The Motley Fool
News headline image
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise ↗
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism. 
Via Stocktwits
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts ↗
Via Stocktwits
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Viking Therapeutics: High Risk, High Reward Play ↗
Via MarketBeat
News headline image
Here's Why This Obesity Drug Company's Share Price Soared Today ↗
The company had positive updates on its clinical trials. 
Via The Motley Fool
Topics Earnings
News headline image
Why Is Viking Therapeutics Stock Rising Today? ↗
Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials. 
Via Benzinga
News headline image
Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside ↗
Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies ↗
Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests. 
Via Investor's Business Daily
News headline image
Viking Therapeutics (NASDAQ:VKTX) Reports Q3 2025 Earnings Miss and 2.8% After-Hours Decline ↗
Viking Therapeutics Q3 2025 results show an earnings miss, with shares falling. The company's key Phase 3 obesity trial remains on track. 
Via Chartmill
Topics Earnings
News headline image
Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck. 
Via Benzinga
News headline image
Earnings Scheduled For October 22, 2025 ↗
 
Via Benzinga
News headline image
These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond ↗
These companies are jockeying for position in a potential $150 billion market opportunity. 
Via The Motley Fool
News headline image
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street? ↗
These stocks have climbed in the triple digits over the past few years. 
Via The Motley Fool
News headline image
Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly? ↗
The smaller drugmaker is looking to disrupt a fast-growing market. 
Via The Motley Fool
News headline image
Down 44%, Should You Buy the Dip on Viking Therapeutics? ↗
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
News headline image
4 Healthcare Stocks to Buy Now ↗
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Shares in Viking Therapeutics Surged This Week ↗
The small-cap pharmaceutical company may be the next in line as takeover fever heats up. 
Via The Motley Fool
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Buying these three stocks offers you instant diversification. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why This Beaten-Down GLP-1 Stock Could Be a Steal ↗
There's more to this company than its performance on the stock market this year suggests. 
Via The Motley Fool
News headline image
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. ↗
Investors once speculated that Pfizer might consider acquiring Viking. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.